Year archive

Hutchmed (China) Limited — 2024 filings

All 105 regulatory filings released by Hutchmed (China) Limited (HCM) in 2024, sourced directly from the official regulator.

105 Filings

2024 Period

2024 filings (105)

Filing	Released	Lang
6-K Regulatory Filings	2024-12-31	English
Appointment of Joint Corporate Broker Regulatory Filings	2024-12-31	English
6-K Regulatory Filings	2024-12-30	English
Blocklisting Six Monthly Return Regulatory Filings	2024-12-30	English
6-K Regulatory Filings	2024-12-13	English
HUTCHMED to Receive Milestone Payment from Takeda Regulatory Filings	2024-12-13	English
6-K Regulatory Filings	2024-12-12	English
Breakthrough Therapy Designation in China Regulatory Filings	2024-12-12	English
6-K Regulatory Filings	2024-12-03	English
HUTCHMED and Innovent Announce ELUNATE Approval Regulatory Filings	2024-12-03	English
6-K Regulatory Filings	2024-11-29	English
Total Voting Rights Regulatory Filings	2024-11-29	English
Continued Inclusion of ORPATHYS in China NRDL Regulatory Filings	2024-11-28	English
6-K Regulatory Filings	2024-11-22	English
FRUZAQLA® Launched in Japan by Takeda Regulatory Filings	2024-11-22	English
6-K Board/Management Information	2024-11-20	English
Appointment of Independent Non-executive Director Board/Management Information	2024-11-20	English
6-K Regulatory Filings	2024-11-06	English
Clinical Data to be Presented at ASH and ESMO Asia Regulatory Filings	2024-11-06	English
6-K Regulatory Filings	2024-10-31	English
First Commercial Milestone Payment Regulatory Filings	2024-10-31	English
Total Voting Rights Regulatory Filings	2024-10-31	English
6-K Regulatory Filings	2024-10-21	English
Vesting of awards under the LTIP Director's Dealing	2024-10-21	English
6-K Regulatory Filings	2024-10-16	English
SAVANNAH: clinically meaningful response rate Regulatory Filings	2024-10-16	English
6-K Regulatory Filings	2024-09-24	English
Japan Approval for FRUZAQLA Regulatory Filings	2024-09-24	English
6-K Regulatory Filings	2024-09-09	English
Clinical Data to be Presented at ESMO and WCLC Regulatory Filings	2024-09-09	English
6-K Regulatory Filings	2024-08-30	English
Total Voting Rights Regulatory Filings	2024-08-30	English
Update on Fruquintinib for Gastric Cancer in China Regulatory Filings	2024-08-30	English
6-K Regulatory Filings	2024-08-22	English
Standard form for notification of major holdings Major Shareholding Notification	2024-08-22	English
6-K Regulatory Filings	2024-08-21	English
HUTCHMED to Host Expert Call to discuss ITP Regulatory Filings	2024-08-21	English
6-K Regulatory Filings	2024-08-06	English
LTIP and Share Option Scheme Regulatory Filings	2024-08-06	English
6-K Regulatory Filings	2024-07-31	English
2024 Interim Results and Business Updates Interim / Quarterly Report H1 2024	2024-07-31	English
6-K Regulatory Filings	2024-07-05	English
NDA Acceptance in China for Tazemetostat Regulatory Filings	2024-07-04	English
Overseas Regulatory Announcement: Form F-3 Filing Regulatory Filings	2024-06-28	English
6-K Regulatory Filings	2024-06-28	English
F-3ASR Capital/Financing Update	2024-06-28	English
Blocklisting Six Monthly Return Regulatory Filings	2024-06-28	English
Total Voting Rights Regulatory Filings	2024-06-28	English
6-K Report Publication Announcement	2024-06-26	English
HUTCHMED to Announce 2024 HY Financial Results Report Publication Announcement	2024-06-26	English
6-K Regulatory Filings	2024-06-24	English
Save the Date: HUTCHMED to Present R&D Updates Regulatory Filings	2024-06-24	English
European Commission Approval for FRUZAQLA Regulatory Filings	2024-06-24	English
6-K Regulatory Filings	2024-06-17	English
Lancet Publish Phase III ESLIM-01 Results Regulatory Filings	2024-06-17	English
6-K Regulatory Filings	2024-06-07	English
HUTCHMED Initiates Phase I Trial of HMPL-506 Regulatory Filings	2024-06-07	English
6-K Regulatory Filings	2024-06-03	English
Nature Medicine Publish Phase III FRUTIGA Results Regulatory Filings	2024-06-03	English
6-K Regulatory Filings	2024-05-31	English
Total Voting Rights Regulatory Filings	2024-05-31	English
6-K Regulatory Filings	2024-05-24	English
HUTCHMED Presentations at 2024 ASCO Annual Meeting Regulatory Filings	2024-05-24	English
6-K Regulatory Filings	2024-05-17	English
Retirement of Chairman and new Chairman appointed Board/Management Information	2024-05-17	English
HUTCHMED Data to be Presented at EHA2024 Congress Regulatory Filings	2024-05-17	English
6-K Regulatory Filings	2024-05-14	English
HUTCHMED Initiates Registrational Phase III Trial Regulatory Filings	2024-05-14	English
HUTCHMED Initiates Phase II/III Trial with Hengrui Regulatory Filings	2024-05-14	English
6-K Declaration of Voting Results & Voting Rights Announcements	2024-05-10	English
Result of AGM Declaration of Voting Results & Voting Rights Announcements	2024-05-10	English
6-K Board/Management Information	2024-05-08	English
Directorate Change Board/Management Information	2024-05-08	English
6-K Regulatory Filings	2024-04-29	English
Positive CHMP Opinion for Fruquintinib Regulatory Filings	2024-04-26	English
6-K Regulatory Filings	2024-04-22	English
Vesting of Awards Under the LTIP Director's Dealing	2024-04-22	English
FORM 6-K Regulatory Filings	2024-04-08	English
2023 Annual Report and Notice of AGM Report Publication Announcement	2024-04-08	English
6-K Regulatory Filings	2024-04-05	English
Data to be Presented at AACR Congress 2024 Regulatory Filings	2024-04-05	English
6-K Regulatory Filings	2024-04-02	English
HUTCHMED and Innovent Announce NDA Acceptance Regulatory Filings	2024-04-02	English
6-K Regulatory Filings	2024-03-28	English
Savolitinib sNDA Accepted in China Regulatory Filings	2024-03-28	English
6-K Regulatory Filings	2024-03-22	English
Initiation of Registration Stage of P2/3 Trial Regulatory Filings	2024-03-22	English
6-K Regulatory Filings	2024-03-14	English
LTIP and Share Option Scheme Regulatory Filings	2024-03-14	English
6-K Regulatory Filings	2024-03-05	English
Vesting of awards under the LTIP Director's Dealing	2024-03-05	English
Publication of Form 20-F Report Publication Announcement	2024-02-28	English
FORM 6-K Regulatory Filings	2024-02-28	English
FORM 20-F Annual Report FY 2023	2024-02-28	English
2023 Full Year Results and Business Updates Earnings Release FY 2023	2024-02-28	English
6-K Regulatory Filings	2024-02-07	English
Presentation of Phase III Data on Fruquintinib Regulatory Filings	2024-02-07	English
6-K Regulatory Filings	2024-02-02	English
Inmagene Exercises Option for Two Drug Candidates Regulatory Filings	2024-02-02	English
6-K Report Publication Announcement	2024-02-01	English
HUTCHMED to Announce 2023 Final Results Report Publication Announcement	2024-02-01	English
6-K Regulatory Filings	2024-01-30	English
HUTCHMED Receives Marketing Approval in Hong Kong Regulatory Filings	2024-01-30	English
6-K Regulatory Filings	2024-01-11	English
Sovleplenib NDA Granted Priority Review in China Regulatory Filings	2024-01-11	English

Filings by year

2026 30 filings
2025 104 filings
2024 105 filings
2023 108 filings
2022 96 filings
2021 149 filings
2020 122 filings
2019 71 filings
2018 77 filings
2017 88 filings
2016 81 filings
2015 53 filings
2014 28 filings
2013 23 filings